Statement regarding speculations on a potential sale of the Partner Products business area
Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO: SOBI) today confirms that the company is in discussions with a private equity firm regarding a possible sale of its Partner Products business area excluding Kineret® and Orfadin®. The discussions may or may not lead to an agreement.
“We have noted specific information in the market regarding a possible sale of Sobi Partner Products. We confirm that we are in discussions which may or may not lead to an agreement”, said Geoffrey McDonough, CEO and President.
This information is information that Swedish Orphan Biovitrum AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of Linda Holmström, Senior Communications Manager, at 14:23 CET on 3 February 2017.
Sobi is an international specialty healthcare company dedicated to rare diseases. Sobi’s mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. Sobi also markets a portfolio of specialty and rare disease products across Europe, the Middle East, North Africa and Russia for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2015, Sobi had total revenues of SEK 3.2 billion (USD 385 M) and about 700 employees. The share (STO: SOBI) is listed on Nasdaq Stockholm. More information is available at www.sobi.com.
|For more information, please contact:|
|Media relations||Investor relations|
|Morten Grøn, Vice President, Head of Communications||Jörgen Winroth, Vice President, Head of Investor Relations|
|+45 25 56 47 81||+1 347-224-0819, +1 212-579-0506, 08 697 2135|
Swedish Orphan Biovitrum AB
Postal address SE-112 76 Stockholm, Sweden
Phone: 46 8 697 20 00 www.sobi.com